Home >Research Discovery>Translation Research
Introduction of group leader
Office phone: +82-31-8018-8009
Email: kaapjoo.park at ip-korea.org
Office location: R5.03
The Medicinal Chemistry group focuses on the optimization of compounds, which are identified through primary screening as being effective against target diseases. The optimization process is a multidisciplinary task to improve potential of becoming a new drug by optimizing biological activity, selectivity, physicochemical properties, in vivo properties and safety. Within the context of cell-based assays, optimization to create drug candidates is accelerated by eliminating unsatisfactory compounds, which have low cell permeability, as well as cytotoxicity, while evaluating biological activity. Additionally, integration of evaluating in vivo properties and toxicity make our drug discovery process faster and more efficient. Thereby qualified advanced molecules or preclinical candidates are created through lead optimization and our ample experience and creativity leads to successful research results.
Currently, we have entered into R&D agreement with Korea Drug Development Fund (KDDF) for ‘Discovery of novel anti-tubercular agent for the treatment of multidrug-resistant/extensively drug-resistant tuberculosis’, and have received funding for research and treatment from KDDF for 18 months.
IPK has established the PROTAC project as a new platform technology for developing new medicines. PROTAC is a new technology in the development of new medicines, which is a spotlighted as a molecule that degrades proteins, and it is been applied to areas such as anti-cancer.
The Medicinal Chemistry group’s area of expertise lies in diseases like tuberculosis, cancer, hepatitis C, influenza, antibiotics etc.
Our areas of activity include:
• Advancing and accelerating the optimization on drug discovery program
• Developing novel chemical platform technology for innovative drug discovery
• Developing probe molecules for identifying target and understanding the in vivo mechanism of drug candidates
• Developing tool compounds for monitoring drug localization in either the cell or living animal
• Providing open-analysis service and support to academia and pharmaceutical companies through collaboration as well as giving access to IPK’s well-equipped infrastructure